[Alpha Biz=(Chicago) Reporter Kim Jisun] Samsung BioLogics surpassed 1 trillion won in quarterly sales for the first time since its foundation due to sales reflection from the operation of its fourth plant and increased efficiency in operating its plant.

Samsung BioLogics announced on the 26th that it recorded consolidated sales of 1.34 trillion won and operating profit of 318.5 billion won in the third quarter of 2023. Sales rose 161 billion won (18%) year-on-year due to a rise in the operation rate of the plant's fourth plant, achieving the highest quarterly performance ever.

Accumulated sales in the third quarter were 2.6211 trillion won and operating profit was 763.7 billion won, up 585.3 billion won (29%) and 92.9 billion won (14%), respectively, from a year earlier. Earlier, Samsung BioLogics offered more than 3.6016 trillion won in annual sales guidance (estimated) in 2023, up more than 20% from a year earlier.

Samsung BioLogics' sales and operating profit for the third quarter were 882.7 billion won and 381.6 billion won, respectively, up 208.1 billion won (31 percent) and 70.2 billion won (23 percent) from a year earlier. The operating profit ratio for the third quarter was 43.2%.

Samsung Bioepis, a subsidiary, posted sales of 262.1 billion won and operating profit of 49.2 billion won in the third quarter of 2023. In the third quarter of last year, sales fell 7.7 billion won (3%) and operating profit fell 28.7 billion won (37%) year-on-year due to temporary base effects from the receipt of U.S. product licensing milestone.

In particular, Samsung BioLogics signed a large-scale consignment production contract with Big Pharma such as Pfizer and Novartis, exceeding 2.726 trillion won in annual orders. This is the highest annual order performance. The cumulative order amount as of October is about $ 11.8 billion. In addition, it secured a total of 14 of the top 20 global pharmaceutical companies as customers and proved its competitiveness in winning orders.

 

[ⓒ AlphaBIZ. 무단전재-재배포 금지]